Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Saint Joseph Oncology, Inc.
211
mi
from
Saint Joseph, MO
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Saint Joseph Oncology, Inc.
211
mi
from
Saint Joseph, MO
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Cox Medical Center South
252
mi
from
Springfield, MO
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Cox Medical Center South
252
mi
from
Springfield, MO
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital Springfield
251
mi
from
Springfield, MO
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital Springfield
251
mi
from
Springfield, MO
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Nebraska Methodist Hospital
260
mi
from
Omaha, NE
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Nebraska Methodist Hospital
260
mi
from
Omaha, NE
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
New York Oncology Hematology PC-Albany
1308
mi
from
Albany, NY
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
New York Oncology Hematology PC-Albany
1308
mi
from
Albany, NY
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
New York Oncology Hematology, PC at Albany Medical Center
1307
mi
from
Albany, NY
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
New York Oncology Hematology, PC at Albany Medical Center
1307
mi
from
Albany, NY
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology Associates of Central New York-Auburn
1171
mi
from
Auburn, NY
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology Associates of Central New York-Auburn
1171
mi
from
Auburn, NY
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center - Moses Campus
1294
mi
from
Bronx, NY
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center - Moses Campus
1294
mi
from
Bronx, NY
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology Associates of Central New York PC-East Syracuse
1197
mi
from
East Syracuse, NY
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology Associates of Central New York PC-East Syracuse
1197
mi
from
East Syracuse, NY
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology Associates of Central New York-Liverpool
1190
mi
from
Liverpool, NY
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology Associates of Central New York-Liverpool
1190
mi
from
Liverpool, NY
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology Associates of Central New York-Rome
1230
mi
from
Rome, NY
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology Associates of Central New York-Rome
1230
mi
from
Rome, NY
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology Associates of Central New York-Onondaga Hill
1191
mi
from
Syracuse, NY
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology Associates of Central New York-Onondaga Hill
1191
mi
from
Syracuse, NY
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Mission Hospital-Memorial Campus
857
mi
from
Asheville, NC
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Mission Hospital-Memorial Campus
857
mi
from
Asheville, NC
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Rutherford Hospital
893
mi
from
Rutherfordton, NC
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Rutherford Hospital
893
mi
from
Rutherfordton, NC
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Summa Barberton Hospital
893
mi
from
Barberton, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Summa Barberton Hospital
893
mi
from
Barberton, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Strecker Cancer Center-Belpre
881
mi
from
Belpre, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Strecker Cancer Center-Belpre
881
mi
from
Belpre, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Adena Regional Medical Center
808
mi
from
Chillicothe, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Adena Regional Medical Center
808
mi
from
Chillicothe, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Doctors Hospital
810
mi
from
Columbus, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Doctors Hospital
810
mi
from
Columbus, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
The Mark H. Zangmeister Center
815
mi
from
Columbus, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
The Mark H. Zangmeister Center
815
mi
from
Columbus, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Grant Medical Center
810
mi
from
Columbus, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Grant Medical Center
810
mi
from
Columbus, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Columbus Oncology and Hematology Associates Inc
809
mi
from
Columbus, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Columbus Oncology and Hematology Associates Inc
809
mi
from
Columbus, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Riverside Methodist Hospital
810
mi
from
Columbus, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Riverside Methodist Hospital
810
mi
from
Columbus, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Delaware Health Center-Grady Cancer Center
809
mi
from
Delaware, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Delaware Health Center-Grady Cancer Center
809
mi
from
Delaware, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Delaware Radiation Oncology
810
mi
from
Delaware, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Delaware Radiation Oncology
810
mi
from
Delaware, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Grady Memorial Hospital
810
mi
from
Delaware, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Grady Memorial Hospital
810
mi
from
Delaware, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Lancaster Radiation Oncology
830
mi
from
Lancaster, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Lancaster Radiation Oncology
830
mi
from
Lancaster, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Fairfield Medical Center
829
mi
from
Lancaster, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Fairfield Medical Center
829
mi
from
Lancaster, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Marietta Memorial Hospital
889
mi
from
Marietta, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Marietta Memorial Hospital
889
mi
from
Marietta, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Summa Health Center at Lake Medina
883
mi
from
Medina, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Summa Health Center at Lake Medina
883
mi
from
Medina, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Knox Community Hospital
841
mi
from
Mount Vernon, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Knox Community Hospital
841
mi
from
Mount Vernon, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Licking Memorial Hospital
843
mi
from
Newark, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Licking Memorial Hospital
843
mi
from
Newark, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Newark Radiation Oncology
843
mi
from
Newark, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Newark Radiation Oncology
843
mi
from
Newark, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Southern Ohio Medical Center
806
mi
from
Portsmouth, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Southern Ohio Medical Center
806
mi
from
Portsmouth, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Springfield Regional Medical Center
770
mi
from
Springfield, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Springfield Regional Medical Center
770
mi
from
Springfield, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
University Pointe
732
mi
from
West Chester, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
University Pointe
732
mi
from
West Chester, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Mount Carmel St. Ann's
815
mi
from
Westerville, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Mount Carmel St. Ann's
815
mi
from
Westerville, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
University of Oklahoma Health Sciences Center
153
mi
from
Oklahoma City, OK
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
University of Oklahoma Health Sciences Center
153
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Natalie Warren Bryant Cancer Center at Saint Francis
156
mi
from
Tulsa, OK
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Natalie Warren Bryant Cancer Center at Saint Francis
156
mi
from
Tulsa, OK
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Clackamas Radiation Oncology Center
1375
mi
from
Clackamas, OR
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Clackamas Radiation Oncology Center
1375
mi
from
Clackamas, OR
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Willamette Valley Cancer Center
1382
mi
from
Eugene, OR
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Willamette Valley Cancer Center
1382
mi
from
Eugene, OR
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Providence Portland Medical Center
1383
mi
from
Portland, OR
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Providence Portland Medical Center
1383
mi
from
Portland, OR
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Saint Luke's University Hospital-Bethlehem Campus
1215
mi
from
Bethlehem, PA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Saint Luke's University Hospital-Bethlehem Campus
1215
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Bryn Mawr Hospital
1216
mi
from
Bryn Mawr, PA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Bryn Mawr Hospital
1216
mi
from
Bryn Mawr, PA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
UPMC Cancer Center at UPMC Horizon
952
mi
from
Farrell, PA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
UPMC Cancer Center at UPMC Horizon
952
mi
from
Farrell, PA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Adams Cancer Center
1115
mi
from
Gettysburg, PA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Adams Cancer Center
1115
mi
from
Gettysburg, PA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
UPMC Cancer Centers - Arnold Palmer Pavilion
995
mi
from
Greensburg, PA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
UPMC Cancer Centers - Arnold Palmer Pavilion
995
mi
from
Greensburg, PA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Cherry Tree Cancer Center
1129
mi
from
Hanover, PA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Cherry Tree Cancer Center
1129
mi
from
Hanover, PA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
UPMC-Johnstown/John P. Murtha Regional Cancer Center
1028
mi
from
Johnstown, PA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
UPMC-Johnstown/John P. Murtha Regional Cancer Center
1028
mi
from
Johnstown, PA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Lancaster General Hospital
1163
mi
from
Lancaster, PA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Lancaster General Hospital
1163
mi
from
Lancaster, PA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
UPMC Cancer Center at UPMC McKeesport
979
mi
from
McKeesport, PA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
UPMC Cancer Center at UPMC McKeesport
979
mi
from
McKeesport, PA
Click here to add this to my saved trials